ANG Lifesciences India Ltd
ANG Lifesciences India Ltd (ANG) last reported results for the quarter ended Jun 2026, with sales of ₹15.3 crore and net profit of ₹-4.24 crore. ANG Lifesciences India Ltd’s board meets on 12 Oct 2026. The stock last traded at ₹38.6, a market capitalisation of ₹50.4 crore. Over the past 52 weeks the stock has ranged between ₹17.6 and ₹49.7. Figures are as of 6 Oct 2026 and are not real time.
ANG Lifesciences India Ltd share price and key metrics
- Current price
- ₹38.6
- Market cap
- ₹50.4 cr
- Book value
- ₹40.5
- ROE
- -16.5%
- ROCE
- -2.32%
- Dividend yield
- 0.00%
- 52w high / low
- 49.7/17.6
Metrics as of 6 Oct 2026. Not real time.
Track ANG Lifesciences India Ltd
Cruxal reads every ANG Lifesciences India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
ANG Lifesciences India Ltd growth and returns
- 10 Years
- %
- 5 Years
- -10%
- 3 Years
- -25%
- TTM
- -16%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -17%
- 10 Years
- %
- 5 Years
- -36%
- 3 Years
- -18%
- 1 Year
- 13%
- 10 Years
- %
- 5 Years
- 3%
- 3 Years
- -14%
- Last Year
- -16%
ANG Lifesciences India Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹15.3 cr, down 37.8% from ₹24.6 cr a year earlier. Net profit was ₹-4.24 cr, down 110.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 32.88 | 24.73 | 16.82 | 24.6 | 26.05 | 18.73 | 23.5 | 15.3 |
| Expenses | 30.6 | 26.88 | 17.52 | 23.95 | 25.97 | 21.41 | 20.82 | 17.25 |
| Operating profit | 2.28 | -2.15 | -0.7 | 0.65 | 0.08 | -2.68 | 2.68 | -1.95 |
| OPM % | 6.93% | -8.69% | -4.16% | 2.64% | 0.31% | -14.31% | 11.40% | -12.75% |
| Other income | 0.35 | -0.27 | 0.65 | 0.09 | 0.12 | 0.16 | 0.17 | 0.11 |
| Interest | 2.18 | 2 | 2.42 | 1.94 | 1.89 | 1.93 | 2.18 | 2.24 |
| Depreciation | 1.74 | 1.96 | 1.42 | 1.53 | 1.52 | 1.51 | 1.77 | 1.5 |
| Profit before tax | -1.29 | -6.38 | -3.89 | -2.73 | -3.21 | -5.96 | -1.1 | -5.58 |
| Tax % | 62.02% | -18.65% | -47.04% | -26.74% | -8.41% | -20.30% | 25.45% | -24.01% |
| Net profit | -2.09 | -5.19 | -2.06 | -2.01 | -2.95 | -4.75 | -1.38 | -4.24 |
| EPS (₹) | -1.60 | -3.97 | -1.58 | -1.54 | -2.26 | -3.64 | -1.06 | -3.25 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
ANG Lifesciences India Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 154 | 354 | 220 | 145 | 93 | 93 | 84 |
| Operating profit | 14 | 68 | 15 | 10 | -1 | 3 | -2 |
| OPM % | 9% | 19% | 7% | 7% | -1.6% | 2.8% | -2.2% |
| Net profit | 7 | 40 | -0 | -10 | -12 | -11 | -13 |
| EPS (₹) | 5.26 | 31.02 | -0.20 | -7.77 | -9.50 | -8.49 | -10.21 |
TTM is the trailing twelve months to the most recent quarter.
ANG Lifesciences India Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 10 | 13 | 13 | 13 | 13 |
| Reserves | 73 | 73 | 63 | 51 | 40 |
| Borrowings | 77 | 71 | 73 | 83 | 79 |
| Other liabilities | 130 | 119 | 92 | 82 | 78 |
| Total liabilities | 290 | 276 | 241 | 230 | 210 |
| Fixed assets | 93 | 88 | 58 | 57 | 51 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other assets | 198 | 188 | 183 | 172 | 160 |
| Total assets | 290 | 276 | 241 | 230 | 210 |
As reported by the company. Total assets equal total liabilities by construction.
ANG Lifesciences India Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 25 | 26 | -9 | -0 | 11 |
| Cash from investing | -44 | -9 | 20 | -2 | 1 |
| Cash from financing | 20 | -17 | -10 | 2 | -12 |
| Net cash flow | 0 | -0 | -0 | -0 | 0 |
| Free cash flow | -17 | 16 | 9 | -4 | 11 |
| CFO / operating profit | 37% | 202% | 39% | -272% | 429% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
ANG Lifesciences India Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | 9% | 1% | -4% | -2% |
| Debtor days | 105 | 138 | 184 | 262 | 267 |
| Inventory days | 59 | 118 | 183 | 331 | 288 |
| Days payable | 113 | 165 | 254 | 405 | 317 |
| Cash conversion cycle | 51 | 91 | 113 | 189 | 238 |
| Working capital days | 20 | 24 | 58 | 72 | -8 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
ANG Lifesciences India Ltd shareholding pattern
Promoters held 70.60% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% |
| Public | 29.39% | 29.39% | 29.39% | 29.40% | 29.40% | 29.41% | 29.40% | 29.40% |
| No. of shareholders | 6,468 | 6,517 | 6,508 | 6,400 | 6,273 | 6,084 | 5,952 | 5,946 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When does ANG Lifesciences India Ltd’s board next meet?
ANG Lifesciences India Ltd’s board meets on 12 Oct 2026.
- Board meetingReappointment of Independent Director Mrs. Chetna for 5-year term
See the full results calendar for every Indian company reporting in the next 30 days.
ANG Lifesciences India Ltd corporate filings
- ANG Lifesciences India Limited Conducts AGM with 100% Approval for Financial and Board ResolutionsAGM/EGMmedium impact
Cruxal's analysis: ANG Lifesciences India Limited held its 20th AGM on 30th September 2026, with all…
Read the full analysis - ANG Lifesciences India Limited Reappoints Independent Director for 5-Year Term, No Immediate Financial ImpactCompany Updatelow impact
Cruxal's analysis: ANG Lifesciences India Limited has announced the reappointment of Mrs. Chetna as an…
Read the full analysis - ANG Lifesciences India Limited holds 20th AGM; no immediate financial disclosures or strategic updates providedAGM/EGMlow impact
Cruxal's analysis: The company conducted its 20th Annual General Meeting on September 30, 2026, via VC/OAVM…
Read the full analysis - Intimation of Closure of Trading Window.Insider Trading / SASTlow impact
- ANG Lifesciences India Ltd schedules 20th Annual General Meeting for September 30, 2026Otherslow impact
Cruxal's analysis: ANG Lifesciences India Ltd has released its Annual Report for FY 2025-26 and issued a…
Read the full analysis - ANG Lifesciences India Limited Announces 20th Annual General Meeting for September 30, 2026AGM/EGMlow impact
Cruxal's analysis: ANG Lifesciences India Limited has issued a notice for its 20th Annual General Meeting…
Read the full analysis - ANG Lifesciences India Ltd announces book closure for upcoming corporate eventCorp. Actionlow impact
Cruxal's analysis: ANG Lifesciences India Ltd has issued an intimation regarding the closure of its register…
Read the full analysis - ANG Lifesciences India Limited schedules 20th Annual General Meeting for September 30, 2026AGM/EGMlow impact
Cruxal's analysis: ANG Lifesciences India Limited has formally intimated the BSE regarding the scheduling of…
Read the full analysis - ANG Lifesciences India Limited Announces Board Meeting Outcome Regarding 20th Annual General Meeting and Director Re-appointmentsOtherslow impact
Cruxal's analysis: ANG Lifesciences India Limited has disclosed the outcome of its board meeting held on…
Read the full analysis - ANG Lifesciences reports significant quarterly losses for Q1 FY2027 with continued operational headwindsBoard Meetinghigh impact
Cruxal's analysis: ANG Lifesciences India Limited reported a weak financial performance for the quarter…
Read the full analysis - ANG Lifesciences India Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: ANG Lifesciences India Limited has issued a formal intimation regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.